Four major advances in treatment of late stage prostate cancer in 2012


In a new paper in the Journal of Clinical Oncology, the American Society for Clinical Oncology (ASCO) has identified four significant advances in the treatment of late stage prostate cancer during 2012.

According to the paper by Roth et al., these advances are:

  • The demonstration of effectiveness of enzalutamide (Xtandi®) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) previously treated with docetaxel-based chemotherapy
  • The demonstration of effectiveness of abiraterone acetate (Zytiga®) in the treatment of men with chemotherapy-naive mCRPC
  • Greater insight into the most appropriate treatment schedules for androgen deprivation therapy (ADT) for men with metastatic prostate cancer
  • The demonstration of effectiveness of injectable radium-223 as a systemic agent for the treatment of bone metastases among men with mCRPC

The full text of this article (which addresses significant advances in the treatment of many forms of cancer, and not just prostate cancer) is available on line.

The “New” Prostate Cancer InfoLink is pleased to note the following comment (see p. 11) in this article, which refers specifically to the appropriate use of continuous or intermittent ADT in carefully selected patients:

In the case of [patients with]minimal disease spread, physicians should discuss both treatment options with patients, because intermittent therapy may not be as beneficial in terms of extending survival as continuous therapy. The decision to administer intermittent androgen-deprivation therapy should be individualized and be based at least in part on the stage of the cancer.

Trials conducted to date have not, in our opinion, fully characterized either the most appropriate form and scheduling of intermittent ADT or the characteristics of those patients who may most benefit from this type of treatment. The fact that it can take some 20 years to complete trials that allow us to make decisions about such issues makes funding of such studies a particularly difficult issue.

5 Responses

  1. 2012 has been quite a year, hasn’t it!

    I started the year on docetaxel, which I did not tolerate well, and it had no effect on my PSA, followed by 6 months of abiraterone, which I tolerated very well, but saw my PSA grow from 10 to 570 during that time. I then took a month off from anything before starting enzalutamide, and saw my PSA go from 570 to 45 during that fallow month. Now into second week of enzalutamide, with no real side effects.

    I wonder what happens next. …

  2. Mike,

    Thanks for another year of good solid information from the site. Always know your efforts are sincerely appreciated.

    Bill

  3. Hi David.

    I’m almost in the same stage/position, finished docetaxel treatment and, after 6 months on abiraterone, no success. …

    Now I’m starting enzalutamide and hoping for better days. …

    Your response is very encouraging.

    Wish you all the best,

    Yosef

  4. Good luck Yosef. How did your PSA move after you stopped the abiraterone?

    David

  5. Up to 1000

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

<span>%d</span> bloggers like this: